HSBC Maintains Buy on Pfizer, Raises Price Target to $32

Benzinga Newsdesk www.benzinga.com Positive 73.9%

Neg 0% Neu 0% Pos 73.9%

HSBC analyst Rajesh Kumar maintains Pfizer (NYSE:PFE) with a Buy and raises the price target from $29 to $32.

Comments

No comments yet. Be the first!